Healthcare provider profile · identity verified

Grant Hsing, MD

Allopathic & Osteopathic Physicians|Family Medicine · CUMMING, GA · NPI 1568684322

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Grant Hsing, MD received $23.32 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$23.32

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$23.32	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$23.32	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$23.32	1	2025
Source payment records 2025-03-11 · Lilly USA, LLC · $23.32 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$23.32	1	2025
Source payment records 2025-03-11 · Lilly USA, LLC · $23.32 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
MOUNJARO mounjaro	2025	Mounjaro	2024	44 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	316	97
Levothyroxine Sodium	Levothyroxine Sodium	264	70
Lisinopril	Lisinopril	232	74
Amlodipine Besylate	Amlodipine Besylate	215	66
Losartan Potassium	Losartan Potassium	186	49
Metformin Hcl	Metformin Hcl	177	57
Prednisone	Prednisone	166	111
Pantoprazole Sodium	Pantoprazole Sodium	155	57
Gabapentin	Gabapentin	150	57
Tamsulosin Hcl	Tamsulosin Hcl	148	50
Rosuvastatin Calcium	Rosuvastatin Calcium	127	45
Metoprolol Succinate	Metoprolol Succinate	112	32
Simvastatin	Simvastatin	111	29
Ezetimibe	Ezetimibe	110	35
Trazodone Hcl	Trazodone Hcl	109	47
Omeprazole	Omeprazole	104	31
Doxycycline Hyclate	Doxycycline Hyclate	103	82
Pravastatin Sodium	Pravastatin Sodium	103	30
Escitalopram Oxalate	Escitalopram Oxalate	101	26
Allopurinol	Allopurinol	99	30
Duloxetine Hcl	Duloxetine Hcl	82	25
Ozempic	Semaglutide	81	16
Synthroid	Levothyroxine Sodium	81	19
Fluconazole	Fluconazole	79	50
Albuterol Sulfate Hfa	Albuterol Sulfate	72	49
Hydrochlorothiazide	Hydrochlorothiazide	72	23
Montelukast Sodium	Montelukast Sodium	72	26
Glipizide	Glipizide	69	21
Azithromycin	Azithromycin	66	55
Sertraline Hcl	Sertraline Hcl	61	22
Amoxicillin	Amoxicillin	60	49
Cephalexin	Cephalexin	59	44
Diclofenac Sodium	Diclofenac Sodium	59	40
Fluoxetine Hcl	Fluoxetine Hcl	55	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	51	38
Meloxicam	Meloxicam	51	22
Carvedilol	Carvedilol	48	13
Metoprolol Tartrate	Metoprolol Tartrate	46	15
Mounjaro	Tirzepatide	44	suppressed
Fluticasone Propionate	Fluticasone Propionate	42	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	36
Furosemide	Furosemide	40	28
Famotidine	Famotidine	38	19
Alprazolam	Alprazolam	36	12
Buspirone Hcl	Buspirone Hcl	36	16
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	30
Hydroxyzine Hcl	Hydroxyzine Hcl	34	19
Clonidine Hcl	Clonidine Hcl	33	13
Donepezil Hcl	Donepezil Hcl	33	suppressed
Ipratropium Bromide	Ipratropium Bromide	33	26
Metformin Hcl Er	Metformin Hcl	33	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Glimepiride	Glimepiride	32	11
Paroxetine Hcl	Paroxetine Hcl	32	suppressed
Potassium Chloride	Potassium Chloride	32	20
Atenolol	Atenolol	31	suppressed
Eliquis	Apixaban	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	suppressed
Valacyclovir	Valacyclovir Hcl	31	18
Azelastine Hcl	Azelastine Hcl	30	14
Finasteride	Finasteride	30	11
Januvia	Sitagliptin Phosphate	30	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	30	12
Triamcinolone Acetonide	Triamcinolone Acetonide	29	23
Bupropion Hcl Sr	Bupropion Hcl	28	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	27	21
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	22
Dicyclomine Hcl	Dicyclomine Hcl	25	16
Lovastatin	Lovastatin	25	suppressed
Mupirocin	Mupirocin	25	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Ondansetron Odt	Ondansetron	23	18
Pregabalin	Pregabalin	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Tramadol Hcl	Tramadol Hcl	22	17
Benazepril Hcl	Benazepril Hcl	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	16
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Ketoconazole	Ketoconazole	19	16
Propranolol Hcl	Propranolol Hcl	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Terbinafine Hcl	Terbinafine Hcl	18	18
Bupropion Xl	Bupropion Hcl	17	suppressed
Cefdinir	Cefdinir	17	15
Lamotrigine	Lamotrigine	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	16	suppressed
Colchicine	Colchicine	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Repatha Sureclick	Evolocumab	14	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	11
Lorazepam	Lorazepam	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Dexlansoprazole Dr	Dexlansoprazole	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Primidone	Primidone	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$23.32 · 1 records	Lilly USA, LLC	MOUNJARO, ZEPBOUND	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Mounjaro play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error